Phagenesis Limited is a company that provides a privacy policy for its website, www.phagenesis.com. The company does not collect personal data from users unless they contact them through the contact form.

Shaheen Hamdy

Conor Mulrooney

Phagenesis Limited

Welcome to the Phagenesis LinkedIn page! 

At Phagenesis, we are dedicated to transforming the way dysphagia is treated.Dysphagia, or difficulty swallowing, can be a debilitating condition that affects millions of people worldwide. 

We believe that everyone deserves the ability to enjoy their meals and live their lives to the fullest, which is whywe have developed the Phagenyx - a revolutionary product that uses pharyngeal electrical stimulation (PES) to treat dysphagia. 

The Phagenyx is a simple, non-invasive device that stimulates the nerves in the pharynx, helping patients regain control of their swallowing function. Our product has been rigorously tested in clinical trials and has been shown to significantly improve swallowing ability in patients with dysphagia. 

As a company, we are committed to advancing the field of dysphagia care through innovative technology and evidence-based practices. We work closely with healthcare providers and patients to ensure that our product meets the highest standards of safety and efficacy. 

We are proud to be changing the paradigm of dysphagia care, and we invite you to join us in our mission to improve the lives of millions of people around the world. Follow our page to stay up-to-date on the latest news and developments in dysphagia care, and to learn more about the Phagenyx and how it is helping patients overcome dysphagia.

MedTech Innovator

Inventages Venture Capital Investment Inc.

Phagenesis Ltd

We'll be at #ISC2024 this week in Phoenix, AZ! Dr. Andrei Alexandrov will be sharing observations from the first US patient experiences with the #Phagenyx #Neurostimulation System. Attend his presentation and drop by the booth to learn how Phagenyx can help #stroke #patients  who struggle to swallow. 

Scott Grant
Alyssa Cook
Reinhard Krickl

#justgettingstarted #PES #icu #criticalcare 

#thankyou to the PhEAST Clinical Trial Project Management team for hosting an incredible day of education and training in Nottingham, UK. It really takes a village to execute a clinical trial at the highest level and we couldn’t be more proud to partner with a team like this!

Learn more about the PhEAST trial here - https://lnkd.in/gQnG93Te

#teamworkmakesthedreamwork #phagenyx #pheast #PES #criticalcare #ICU #dysphagia

Another incredible patient story from Banner Health and University of Arizona College of Medicine - Phoenix. Jeremy Hogue, the former University of Southern California #Football  Academic All-American Center suffered a stroke, affecting his speech, the right side of his body and how well he could swallow. 

Under Chief of Neurology Dr. Andrei Alexandrov and the medical and speech-language pathology team at Banner, Jeremy received #neurostimulation treatment with #Phagenyx to restore swallowing control. 

“It’s validating, that’s how I’m feeling. It’s pretty cool to say that I’ve been doing this almost six months and in six days I finally have dramatic improvement."

#believe #teamworkmakesthedreamwork #trojans 

Metric
Company Name	Phagenesis Limited
Symbol
MSH ID	COM:PHAGENESIS
Market	PRIVATE
Sector	Public & Social Sector
Industry	Technology
Country	GB
Stage	Series
Employee Count	21
Website	phagenesis.com
LinkedIn	phagenesis-ltd
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic	3.23K
Web Traffic Growth	0.81
Valuation
Raised Capital	42M

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

COM:PHAGENESIS

Phagenesis Limited

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue